News

December 5, 2019December 5, 2019

Ella the Jellyfish Becomes First Amazon Alexa Skill to Offer Fun and Support for LGS Children

News

Children with Lennox-Gastaut syndrome, and their families and caregivers can now access the first Amazon Alexa skill — called Ella the Jellyfish — that’s designed to provide support and compassion ... Read more

November 21, 2019November 21, 2019

NICE Favors Adding Epidyolex, Cannabidiol Oral Solution, to NHS for Lennox-Gastaut Patients in England

News

The National Institute of Health and Care Excellence (NICE), an arm of the United Kingdom’s public health system, favors use of the oral cannabidiol solution Epidyolex as an add-on to clobazam to ... Read more

November 14, 2019

Rare Disease Film Festival Highlights Patient and Researcher Unity

News

Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: ... Read more

November 14, 2019November 14, 2019

Onfi as Add-on Lennox-Gastaut Therapy Lowers Drop Seizure Rates, Study Reports

News

Onfi (clobazam), as an adjunct seizure treatment for Lennox-Gastaut syndrome (LGS), significantly reduced the number of weekly drop seizures and its effects were maintained in some patients for up to five ... Read more

November 7, 2019November 14, 2019

Enrollment Completed in Phase 3 Trial Testing Fintepla to Treat Seizures in Lennox-Gastaut Syndrome Patients

News

Zogenix has enrolled the last patient in a Phase 3 clinical trial evaluating its lead investigational candidate Fintepla (ZX008) as an add-on therapy for seizures associated with Lennox‑Gastaut syndrome (LGS), the company ... Read more

October 31, 2019November 14, 2019

Long-term Treatment With Soticlestat Induces Sustained Reduction in Seizure Frequency in Rare Epilepsies, Initial Data Show

Just Published, News

Long-term treatment with the investigational oral therapy soticlestat (OV935/TAK-935) can reduce the median seizure frequency by up to 90% in adults with Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies ... Read more

October 24, 2019October 25, 2019

Epidyolex, Oral CBD, Approved in Europe to Treat Lennox-Gastaut and Dravet Syndrome Starting at Age 2

News

The European Commission has approved Epidyolex (cannabidiol, CBD) as an add-on therapy to clobazam to treat seizures associated with Lennox‑Gastaut syndrome (LGS) and Dravet syndrome in patients 2 and older. Epidyolex — which ... Read more